Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 6,190 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Medication Group Clear all

Conditions: Gastric Ultrasound, Glucagon-like Peptide 1, Point of Care Ultrasound
Interventions: Gastric Ultrasound Exam; Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 99 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Jacksonville, Florida • Albany, New York + 2 more

Conditions: Diabetes Mellitus, Chronic Disease
Interventions: Text Messaging (TM), Health Coaching (HC), Enhanced Usual Care (EC); Behavioral
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 19
States / cities: Holly Springs, Mississippi • Bartlett, Tennessee • Covington, Tennessee + 2 more

Conditions: Solid Tumor, Adult, Healthy Donors, COVID-19 Donors
Interventions: Not listed
Lead sponsor: BioCytics, Inc.; Industry
Eligibility: 5 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2030
U.S. locations: 1
States / cities: Huntersville, North Carolina

Conditions: Allergic Rhinitis
Interventions: Grass pollen extract, Placebo injection; Biological · Other
Lead sponsor: Amber Patterson; Other
Eligibility: 15 Years to 24 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy Subjects
Interventions: AC-076 for s.c. administration, Placebo; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Epilepsy
Interventions: Brivaracetam, Lorazepam; Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 14
States / cities: Birmingham, Alabama • Tucson, Arizona • Orlando, Florida + 10 more

Conditions: Osteoarthritis, Hip
Interventions: FX006, Normal saline; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 32
States / cities: Phoenix, Arizona • Tucson, Arizona • Canoga Park, California + 27 more

Conditions: Head and Neck Cancer
Interventions: Placebo, Ketamine Topical; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 99 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Glabellar Rhytides, Frown Lines Between the Eyebrows
Interventions: Mentor Purified Toxin Botulinum Toxin Type A, Preservative-free Saline; Drug
Lead sponsor: Mentor Worldwide, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 699 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Insomnia, Alcohol Use Disorder
Interventions: Cognitive Behavioral Therapy for Insomnia, Sleep Hygiene, Alcohol Use Disorder Treatment as Usual; Behavioral
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Asthma
Interventions: FLOVENT™ DISKUS™ 100 mcg BID, ADVAIR™ DISKUS™ 100/50 mcg BID; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 38
States / cities: Tucson, Arizona • Bakersfield, California • Fresno, California + 33 more

Conditions: HIV Infections
Interventions: Delayed ART, Continuous ART; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 883 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 58
States / cities: Beverly Hills, California • Fresno, California • Mill Valley, California + 24 more

Conditions: Medication-related Osteonecrosis of the Jaw, Bisphosphonate-related Osteonecrosis of the Jaw, Avascular Necrosis
Interventions: Pentoxifylline, Placebo, Tocopherol; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 4
States / cities: Birmingham, Alabama • Ann Arbor, Michigan • Lake Success, New York + 1 more

Conditions: Chemotherapy-Induced Nausea and Vomiting
Interventions: Palonosetron, Ondansetron, Placebo to Ondansetron, Placebo to Palonosetron; Drug
Lead sponsor: Helsinn Healthcare SA; Industry
Eligibility: Up to 16 Years
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 14
States / cities: Little Rock, Arkansas • Duarte, California • Aurora, Colorado + 11 more

Conditions: Cardiovascular Disease, Hypertension, Care Coordination, HIV Treatment Cascade
Interventions: Intervention group, Education control group; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Decatur, Georgia • Baltimore, Maryland • Durham, North Carolina + 1 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Text- Messaging, Treatment as usual; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 6 Years to 17 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acne Vulgaris
Interventions: Vehicle, Tazarotene Cream, 0.1 %, Tazorac Cream, 0.1%; Drug
Lead sponsor: G & W Laboratories Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,741 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Arlington Hts., Illinois

Conditions: Gastroparesis
Interventions: Gastric Electrical Stimulator, Enterra, Medtronics, Inc.; Device
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Hepatitis C Virus Infection
Interventions: LDV/SOF, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tobacco Use
Interventions: Nicotine Replacement Therapy, Counseling; Drug · Behavioral
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years to 64 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Glioma
Interventions: ABY-029; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Preeclampsia, Aspirin, Clinical Decision Support Systems, Economics, Behavioral
Interventions: Electronic health record best practice alert; Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: Female only
Enrollment: 830 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Precancerous Condition
Interventions: celecoxib, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 7
States / cities: Birmingham, Alabama • Irvine, California • Ann Arbor, Michigan + 4 more

Conditions: Acute Peripheral Arterial Occlusion
Interventions: Plasmin, Plasminogen Activator, Placebo; Biological · Other
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 2
States / cities: Buffalo, New York • Cleveland, Ohio

Search by objective public record fields.

Gastric Ultrasound Assessment for Patients Taking GLP1 Agonists

The Management of Diabetes in Everyday Life Program

A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.

Safety of Lymph Node Injection for Allergen Immunotherapy

A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the Body

A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis

Head and Neck Cancer Patients With Oral Mucositis Treated With Ketamine Oral Rinse

Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the Eyebrows

CBT-I on Alcohol Treatment Outcomes Among Veterans

Fall Epidemic Viral Pediatric Study

Effects of Two Anti-HIV Drug Regimens on HIV Transmission Risk Behavior Among SMART Study Participants

Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ)

Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients

A Nurse-led Intervention to Extend the Veteran HIV Treatment Cascade for Cardiovascular Disease Prevention

Text Messaging Adherence to Stimulant Medication

Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris

Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis

Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection

Jail-Based Use of Smoking Cessation Treatment Study

A Microdose Evaluation Study of ABY-029 in Recurrent Glioma

Low Dose Aspirin Alerts in High-Risk Pregnancies

Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses

A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion